Payment overview · 2025
General Payments
$597.60
33 reported records · 12 companies
Healthcare provider profile · identity verified
Krishnaveni Bethi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BEDFORD, TX · NPI 1821067083
Verified facts
What the public records show
CMS Open Payments records show Krishnaveni Bethi, M.D. received $597.60 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.31 | 27.8% | 11 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $82.53 | 13.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.52 | 12.5% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $64.79 | 10.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.23 | 8.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.84 | 6.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.91 | 4.3% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $23.42 | 3.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.13 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.22 | 3.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.62 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.08 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $597.60 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $82.53 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $74.52 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.08 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $64.79 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.59 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
91 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 839 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 821 | 241 |
| Amlodipine Besylate | Amlodipine Besylate | 732 | 224 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 504 | 140 |
| Lisinopril | Lisinopril | 468 | 131 |
| Losartan Potassium | Losartan Potassium | 420 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 348 | 106 |
| Gabapentin | Gabapentin | 281 | 93 |
| Metformin Hcl | Metformin Hcl | 277 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 87 |
| Alendronate Sodium | Alendronate Sodium | 256 | 68 |
| Omeprazole | Omeprazole | 238 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 229 | 57 |
| Metformin Hcl Er | Metformin Hcl | 221 | 60 |
| Trazodone Hcl | Trazodone Hcl | 204 | 59 |
| Simvastatin | Simvastatin | 201 | 56 |
| Furosemide | Furosemide | 189 | 65 |
| Carvedilol | Carvedilol | 178 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 164 | 47 |
| Montelukast Sodium | Montelukast Sodium | 163 | 48 |
| Potassium Chloride | Potassium Chloride | 162 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 37 |
| Eliquis | Apixaban | 132 | 31 |
| Allopurinol | Allopurinol | 119 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 53 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 109 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 28 |
| Glimepiride | Glimepiride | 99 | 28 |
| Sertraline Hcl | Sertraline Hcl | 95 | 27 |
| Ezetimibe | Ezetimibe | 94 | 28 |
| Buspirone Hcl | Buspirone Hcl | 92 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 19 |
| Mounjaro | Tirzepatide | 91 | 17 |
| Synthroid | Levothyroxine Sodium | 88 | 23 |
| Ozempic | Semaglutide | 85 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 82 | 21 |
| Meloxicam | Meloxicam | 81 | 36 |
| Famotidine | Famotidine | 80 | 27 |
| Spironolactone | Spironolactone | 79 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 21 |
| Alprazolam | Alprazolam | 77 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 41 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 18 |
| Prednisone | Prednisone | 70 | 56 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 18 |
| Bupropion Xl | Bupropion Hcl | 67 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 55 |
| Lorazepam | Lorazepam | 64 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 17 |
| Jardiance | Empagliflozin | 56 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 14 |
| Glipizide | Glipizide | 53 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 47 |
| Azithromycin | Azithromycin | 51 | 46 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 21 |
| Memantine Hcl | Memantine Hcl | 48 | 16 |
| Nystatin | Nystatin | 47 | 32 |
| Myrbetriq | Mirabegron | 45 | 11 |
| Tramadol Hcl | Tramadol Hcl | 45 | 17 |
| Estradiol | Estradiol | 43 | 18 |
| Finasteride | Finasteride | 43 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Cefdinir | Cefdinir | 38 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Atenolol | Atenolol | 35 | suppressed |
| Torsemide | Torsemide | 34 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 30 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 29 |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 26 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 14 |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Nadolol | Nadolol | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Azelastine Hcl | Azelastine Hcl | 18 | 13 |
| Mupirocin | Mupirocin | 18 | 12 |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Telmisartan | Telmisartan | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $597.60 · 33 records | Novo Nordisk Inc | ETERNA, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, KISUNLA, LEQVIO, Leqembi, OFEV, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SYMPLICITY G3, Veozah | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error